PP
NERV icon

Paloma Partners’s Minerva Neurosciences NERV Stock Holding History

Paloma Partners’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,778
Closed -$101K – 1788
2019
Q4 		$101K Buy
+1,778
New +$78.4K ﹤0.01% 2050
2018
Q1 		– Sell
-1,900
Closed -$92K – 2155
2017
Q4 		$92K Buy
+1,900
New +$94.2K ﹤0.01% 1798

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
IVAI
Index Venture Associates IV St. Helier, Channel Islands, Jersey $6.24M AUM
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paloma Partners's NERV Position: Q1 2020 in Review

Paloma Partners sold out of Minerva Neurosciences (NERV) in Q1 2020, closing a stake of 1,778 shares — an estimated $101K sold.

Paloma Partners first reported a position in NERV in Q4 2017 and held it in 2 quarters. The position peaked at $101K in Q4 2019. 90 funds tracked by Wall St. Rank hold NERV as of Q1 2020.

  • Paloma Partners reported no remaining Minerva Neurosciences position as of Q1 2020 after selling out during the quarter.
  • Paloma Partners sold 1,778 Minerva Neurosciences shares in Q1 2020, an estimated $101K.
  • Paloma Partners first reported a position in Minerva Neurosciences in Q4 2017 and held it in 2 quarters.
  • Paloma Partners's Minerva Neurosciences position peaked at $101K in Q4 2019.
  • 90 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.